

Category: OTHER SPECIES

What it is:

Tick-Borne Encephalitis (TBE) is an acute viral disease of the central nervous system, caused by the TBE Virus (TBEV), an arbovirus belonging to the genus *Flavivirus*.

TBEV can cause meningitis, encephalitis, and meningoencephalomyelitis in humans and, more rarely, in domestic animals, with potentially severe outcomes and permanent neurological complications.

Categories



TBE virus circulates primarily in nature through a cycle involving ticks and small wild mammals. Ticks may become infected during blood meals on infected hosts. Rodents, such as mice and voles, are the main reservoirs of the virus, maintaining the infection in natural environments.

Other wild animals, such as **deer and birds**, can also contribute to the geographical spread of ticks, although they do not act as reservoirs.

Rarely, livestock such as cattle, goats, and sheep can become infected and transmit the virus to humans through the consumption of raw milk. In addition, both humans and other domestic animals such as dogs and horses may develop clinical disease.

Origin and Transmission

The primary transmission of the virus occurs through the bite of infected ticks, particularly *Ixodes ricinus* in Europe and *Ixodes persulcatus* in Asia. Ticks can transmit the infection during all stages of their life cycle: larva, nymph, and adult.

In rare cases, transmission can also occur through the ingestion of raw milk or unpasteurised dairy products (such as fresh cheeses) from infected ruminants, including goats, sheep, and cattle.

The incubation period ranges from 4 to 28 days, with an average of 7–8 days.

The life cycle of ticks, whose activity in temperate countries is highest from spring through autumn, drives the **seasonal** pattern of the disease.

Symptoms and Impacts

ANIMALS HUMANS In general, infected domestic animals do not show The groups at highest risk are those with greater expoobvious clinical signs. sure, such as agricultural and forestry workers, hunters, In rare cases, dogs or horses may develop encephalitis, hikers, and travelers to endemic areas. presenting with fever, disorientation, or neurological In humans, TBE infection generally follows a biphasic symptoms, although the frequency is low. course. The first phase is characterised by non-specific, flu-like symptoms such as fever, fatigue, headache, muscle pain, and sometimes digestive disturbances. After a few days, these symptoms may resolve; however, in a proportion of cases (10-30%), a more severe second phase follows, during which the virus affects the central nervous system. In this phase, meningitis, encephalitis, or meningoencephalomyelitis may develop, with symptoms including high fever, severe headache, neck stiffness, balance disorders, paralysis, cognitive impairment, and, in the most severe cases, loss of consciousness and coma. Neurological complications may persist long term,

Geographical Distribution

TBE is found mainly in Central, Eastern, and Northern Europe, as well as in parts of Asia (Russia, China, Mongolia). The highest incidence rates are reported in Austria, Slovenia, the Czech Republic, and the Baltic States. In Italy, the disease is endemic in some Alpine and pre-Alpine areas, particularly in Trentino-Alto Adige, Friuli Venezia Giulia, and Veneto. It has also been sporadically detected in Emilia-Romagna, Tuscany, and Lazio.

Preventive Measures

Prevention of tick-borne encephalitis primarily relies on vaccination, which is both effective and recommended for individuals living in or traveling to endemic areas. In addition to vaccination, personal protective measures should be used during outdoor activities in at-risk areas, including wearing clothing that covers the skin, using tick repellents, and thoroughly checking clothing and the body after being in wooded or grassy environments. No specific therapy is available for the disease; therefore, treatment is based on symptomatic and supportive care, as well as the management of complications in severe cases. For this reason, prevention remains the most effective strategy to reduce the risk of infection.









and in severe cases, the disease can be fatal, particularly in elderly, debilitated, or immunocompromised patients. In Europe, **mortality** associated with infection

is estimated at 0.5-2%.

References:

- Centers for Disease Control and prevention (2024). About Tick-borne Encephalitis Virus https://www.cdc.gov/tick-borne-encephalitis/about/index.html
- Centers for Disease Control and prevention (2025). Tick-Borne Encephalitis https://www.cdc.gov/yellow-book/hcp/travel-associated-infections-diseases/tick-borne-encephalitis.html
- European Centre for Disease Control (2024). Factsheet about tick-borne encephalitis (TBE) https://www.ecdc.europa.eu/en/tick-borne-encephalitis/facts/facts/heet
- Istituto Superiore di Sanità, Sorveglianze e registri, Archivio per anni https://www.epicentro.iss.it/archivio/2024/11-1-2024
- Istituto Superiore di Sanità (2024) Meningoencefalite da zecche https://www.epicentro.iss.it/zecche/meningoencefalite
- Istituto Superiore di Sanità, Zanzara tigre, Archivio 2017-2023 https://www.epicentro.iss.it/zanzara/2017-2023
- Morso di zecca. TBE: qual è la situazione in Italia? https://morsodizecca.it/tbe-qual-e-la-situazione-in-italia/
- World health Organization (2025). Tick-borne encephalitis https://www.who.int/health-topics/tick-borne-encephalitis/#tab=tab_1